Effect of topical motesanib in experimental corneal neovascularization model.
Mukaddes ÇelenkHakan YıldırımAhmet TektemurMehmet BalbabaMurat ErdağPublished in: International ophthalmology (2023)
Motesanib with a dose of 7.5 mg/ml statistically significantly suppressed the VEGFR-2 mRNA level compared with other treatment doses and may be more effective than bevacizumab. Further, miRNA-126 can be used as a proangiogenic marker.